organization · Reporting owner
YK Bioventures Opportunities Fund I, L.P.
Disclosed activity across 1 company
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CERO THERAPEUTICS HOLDINGS, INC.
Report date December 11, 2024 · Filed December 13, 2024
Jointly reported with YK Bioventures Opportunities GP I, LLC, Kossar Mitchell William, Yeung Gary Kahing
Section 16 reporting ended · disclosed 2024-12-13. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy YK Bioventures Opportunities Fund I, L.P. | 13,005,169 |
Last balance in matching sequence
After 2024-12-13 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2024-12-11 · Sale · Disposed 1,343,801 · Balance 17,618,618 F1: Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. Row 2 · 2024-12-12 · Sale · Disposed 1,614,541 · Balance 16,004,077 F1: Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. Row 3 · 2024-12-13 · Sale · Disposed 2,998,908 · Balance 13,005,169 F1: Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 13, 2024 Filed Dec 13, 2024 18:41 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | SaleCommon Stock | 2,998,908 | $0.06 | $179,934.48 |
DisclosureSEC source: 0001415889-24-029371 · form4-12132024_111210.xml · nonDerivative · entry 3 YK Bioventures Opportunities GP I, LLC · CIK 0002042634 · 10% owner YK Bioventures Opportunities Fund I, L.P. · CIK 0002042636 · 10% owner Kossar Mitchell William · CIK 0002042691 · 10% owner Yeung Gary Kahing · CIK 0002042700 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By YK Bioventures Opportunities Fund I, L.P. Disclosed balance after: 13,005,169 F1 · ownership.nature: Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 12, 2024 Filed Dec 13, 2024 18:41 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | SaleCommon Stock | 1,614,541 | $0.07 | $113,017.87 |
DisclosureSEC source: 0001415889-24-029371 · form4-12132024_111210.xml · nonDerivative · entry 2 YK Bioventures Opportunities GP I, LLC · CIK 0002042634 · 10% owner YK Bioventures Opportunities Fund I, L.P. · CIK 0002042636 · 10% owner Kossar Mitchell William · CIK 0002042691 · 10% owner Yeung Gary Kahing · CIK 0002042700 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By YK Bioventures Opportunities Fund I, L.P. Disclosed balance after: 16,004,077 F1 · ownership.nature: Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 11, 2024 Filed Dec 13, 2024 18:41 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | SaleCommon Stock | 1,343,801 | $0.08 | $107,504.08 |
DisclosureSEC source: 0001415889-24-029371 · form4-12132024_111210.xml · nonDerivative · entry 1 YK Bioventures Opportunities GP I, LLC · CIK 0002042634 · 10% owner YK Bioventures Opportunities Fund I, L.P. · CIK 0002042636 · 10% owner Kossar Mitchell William · CIK 0002042691 · 10% owner Yeung Gary Kahing · CIK 0002042700 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By YK Bioventures Opportunities Fund I, L.P. Disclosed balance after: 17,618,618 F1 · ownership.nature: Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 10, 2024 Filed Dec 10, 2024 20:44 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | SaleCommon Stock | 1,570,947 | $0.09 | $141,385.23 |
DisclosureSEC source: 0001415889-24-028899 · form4-12112024_011219.xml · nonDerivative · entry 3 YK Bioventures Opportunities GP I, LLC · CIK 0002042634 · 10% owner YK Bioventures Opportunities Fund I, L.P. · CIK 0002042636 · 10% owner Kossar Mitchell William · CIK 0002042691 · 10% owner Yeung Gary Kahing · CIK 0002042700 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By YK Bioventures Opportunities Fund I, L.P. Disclosed balance after: 18,962,419 F1 · ownership.nature: Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 20:44 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | SaleCommon Stock | 850,543 | $0.11 | $93,559.73 |
DisclosureSEC source: 0001415889-24-028899 · form4-12112024_011219.xml · nonDerivative · entry 2 YK Bioventures Opportunities GP I, LLC · CIK 0002042634 · 10% owner YK Bioventures Opportunities Fund I, L.P. · CIK 0002042636 · 10% owner Kossar Mitchell William · CIK 0002042691 · 10% owner Yeung Gary Kahing · CIK 0002042700 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By YK Bioventures Opportunities Fund I, L.P. Disclosed balance after: 20,533,366 F1 · ownership.nature: Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| December 06, 2024 Filed Dec 10, 2024 20:44 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | SaleCommon Stock | 1,236,874 | $0.12 | $148,424.88 |
DisclosureSEC source: 0001415889-24-028899 · form4-12112024_011219.xml · nonDerivative · entry 1 YK Bioventures Opportunities GP I, LLC · CIK 0002042634 · 10% owner YK Bioventures Opportunities Fund I, L.P. · CIK 0002042636 · 10% owner Kossar Mitchell William · CIK 0002042691 · 10% owner Yeung Gary Kahing · CIK 0002042700 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By YK Bioventures Opportunities Fund I, L.P. Disclosed balance after: 21,383,909 F1 · ownership.nature: Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
| October 10, 2024 Filed Nov 14, 2024 20:14 UTC | CERO THERAPEUTICS HOLDINGS, INC. CERO · Entity 8622 | SaleCommon Stock | 3,250,000 | $0.10 | $325,000.00 |
DisclosureSEC source: 0001415889-24-026908 · form4-11152024_011114.xml · nonDerivative · entry 1 YK Bioventures Opportunities GP I, LLC · CIK 0002042634 · 10% owner YK Bioventures Opportunities Fund I, L.P. · CIK 0002042636 · 10% owner Kossar Mitchell William · CIK 0002042691 · 10% owner Yeung Gary Kahing · CIK 0002042700 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: No plan indicated Ownership: Indirect · By YK Bioventures Opportunities Fund I, L.P. Disclosed balance after: 22,620,783 F1 · price: The price reported in Column 4 is a weighted average price. These securities were sold in multiple transactions at prices ranging from $0.09 to $0.10 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of securities sold at each separate price within the range set forth in this footnote. F2 · ownership.nature: Securities are held directly by YK Bioventures Opportunities Fund I, L.P. (f/k/a YK Bioventures, LLC) ("YK Opps I"). YK Bioventures Opportunities GP I, LLC ("YK Opps I GP") is the general partner of YK Opps I and may be deemed to beneficially own the shares held by YK Opps I. Mitchell W. Kossar and Gary K. Yeung are managing partners of YK Opps I GP, and may be deemed to share voting and investment power over the shares held by YK Opps I. Each of YK Opps I GP and Messrs. Kossar and Yeung disclaims beneficial ownership of these shares except to the extent of its or his respective pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.